CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FiercePharma
Original article

{"a":[{"_":"Sandoz floats nearly $500M to resolve bulk of lingering US antitrust claims","$":{"href":"/pharma/sandoz-floats-nearly-500m-resolve-bulk-lingering-us-antitrust-claims","hreflang":"en"}}]}

RegulatoryNegative
AI Analysis

Summary

Sandoz is proposing nearly $500M to settle U.S. antitrust claims in a manner similar to Johnson & Johnson's recent settlement strategy. The settlement would resolve the bulk of lingering antitrust litigation against the generics and biosimilars company.

Outcome Details

Settlement discussions to resolve antitrust claims

Importance:6/10
Sentiment:
-0.30
antitrustlitigationsettlementgenericsbiosimilars
Related Companies

Read the original article

Published by FiercePharma on August 3, 2026 9:29 AM

Read Original